Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer, emphasizing the need for biomarker-driven treatment personalization and ...

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...

An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, ...

An expert discusses the selection of CAR T-cell therapies for third-line large B-cell lymphoma (LBCL), noting that while all ...

In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining ...